GREY:DGCRF - Post by User
Post by
Dibah42on Jul 30, 2014 8:45pm
199 Views
Post# 22796590
From HOLX Q3
From HOLX Q3 Third Quarter Fiscal 2014 Revenue Overview by Segment (Compared to the Third Quarter Fiscal 2013):
- Diagnostics revenues of $293.1 million decreased (1.5)%, primarily due to decreases in ThinPrep pap test sales in the U.S. due to interval expansion and to a lesser extent, blood screening revenues. Partially offsetting these declines was a 7.0% increase in the Company's molecular diagnostics franchise, primarily from the Company's Aptima product line.